JSPR Stockholder Alert: Robbins LLP Reminds Investors of the Securities Fraud Class Action Against Jasper Therapeutics, Inc.

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly misleading investors regarding the commercial prospects of its lead product candidate, Briquilimab, which has resulted in significant stock price decline [1][2][3]. Group 1: Allegations and Issues - The lawsuit claims that Jasper Therapeutics failed to disclose critical information about its manufacturing controls and procedures, which were necessary to ensure compliance with cGMP regulations [2]. - This lack of disclosure allegedly increased the risk of confounding results in ongoing studies, negatively impacting the regulatory and commercial prospects of the company's products, including Briquilimab [2]. - The failure to maintain proper controls also raised the likelihood of disruptive cost-reduction measures, leading to overstated business and financial prospects for the company [2]. Group 2: Stock Price Impact - Following the revelation of these issues on July 7, 2025, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decrease, closing at $3.04 per share [3]. Group 3: Class Action Participation - Shareholders of Jasper Therapeutics may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiffs [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].